Back to top
more

Zai Lab Limited (ZLAB)

(Delayed Data from NSDQ)

$15.66 USD

15.66
434,002

+0.54 (3.57%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $15.68 +0.02 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock

by Zacks Equity Research

Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals

by Zacks Equity Research

Seagen (SGEN) and Genmab announce that the late-stage study of Tivdak in the second-line treatment of adult patients with recurrent or metastatic cervical cancer meets the primary and secondary goals.

Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug

by Zacks Equity Research

Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.

Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up

by Zacks Equity Research

Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.

Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?

by Zacks Equity Research

Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations

by Zacks Equity Research

Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.

Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Does Zai Lab Limited Unsponsored ADR (ZLAB) Have the Potential to Rally 115.25% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at an 115.3% upside potential for Zai Lab Limited Unsponsored ADR (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.

Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The Zacks Analyst Blog Highlights Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com

by Zacks Equity Research

Zai Lab, Li Auto, Dingdong (Cayman), Autohome and JD.com are part of the Zacks top Analyst Blog.

Sejuti Banerjea headshot

Why China Stocks Are Surging This Week

by Sejuti Banerjea

China has its share of problems, yet China stocks appear to be surging this week.

Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates

by Zacks Equity Research

Seagen (SGEN) reports a wider-than-expected loss in the third quarter of 2022 while its revenues beat estimates. The company raises total revenue guidance for 2022.

Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?

by Zacks Equity Research

Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.

Why Earnings Season Could Be Great for Zai Lab (ZLAB)

by Zacks Equity Research

Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Wall Street Analysts Think Zai Lab Limited Unsponsored ADR (ZLAB) Could Surge 145%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Zai Lab Limited Unsponsored ADR (ZLAB) points to a 144.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Deciphera (DCPH) reports wider-than-expected loss and revenue miss in the third quarter. It is gearing up for multiple developments and pipeline updates in the fourth quarter.

Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal

by Zacks Equity Research

Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.

Mark Vickery headshot

Wayfair (W) Celebrates Cinco de Mayo with Big Q1 Beat (revised)

by Mark Vickery

With reopening beginning in certain states around the country, we may see levels of commercial activity reminiscent of this past St Patrick's Day -- a long 7 weeks ago.

Mark Vickery headshot

Wayfair (W) Celebrates Cinco de Mayo with Big Q1 Beat

by Mark Vickery

With reopening beginning in certain states around the country, we may see levels of commercial activity reminiscent of this past St Patrick's Day -- a long 7 weeks ago.

Q1 Earnings and Economic Data Deluge

by Zacks Equity Research

Q1 Earnings and Economic Data Deluge

Is Zai Lab Limited Unsponsored (ZLAB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ZLAB) Outperforming Other Medical Stocks This Year?

Will Zai Lab Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Zai Lab.